Neil Hunn
Analyst · Oppenheimer
Thanks Rob. Let's turn to our Application Software segment. Revenue came in at $405 million, which represented increase of 5% on an organic basis. EBITDA was $168 million, an increase of 7% versus prior year and EBITDA margins were 41.4%. At Deltek we saw the continuation of a few trends that we discussed over the past several quarters. Specifically Deltek grew high single-digits in the quarter following the difficult 2Q comp. In addition, we continue to see a good balance of perpetual software transactions and a continued acceleration in recurring revenues as a result of an increased mix of business towards Deltek SaaS offerings. Also the business continued to see a nice bounce of activity across their two macro end markets, professional services and government contracting. Deltek’s team continues to execute exceptionally well. Also in the quarter, we acquired ComputerEase for a $185 million. ComputerEase is a leading enterprise software solution provider for construction firms with particular emphasis on the smaller end of the market. They have over 6,000 customers in North America and deliver the software on -- either on on-premise basis or in the cloud. This solution is very specific to the needs of building contractors including job costing, construction accounting, project management, asset management as well as payroll. This business fits nicely with Deltek's leadership position and the architecture and engineering vertical. This is a great addition to Delkek's AEC platform. Aderant experienced yet again double-digit growth as a result of continued share gains within the large law vertical and the adoption of their newer SaaS solutions targeting smaller law firms and cross-selling new products to the larger firms. As you may know, we have highlighted Aderant’s competitive strength for several past quarters and are proud of the long-term market share gains by the Aderant team. Strata logged another great quarter based on very strong new logo ads, continued strong renewal activity and the adoption of their new bolt-on products for their cost accounting and decision support SaaS products targeted to the hospital market. Data Innovations and CliniSys performed quite well in the quarter, each up high single-digits. Data Innovations, our global clinical laboratory middleware or connectivity software business continued nice share gains for their core connectivity products. And CliniSys, our European hospital laboratory ERP business continues to benefit from market consolidation in most of the Western European markets. In particular, CliniSys products are essentially the only hospital laboratory ERP products proven to scale to meet the needs of the larger consolidated customers. We're quite bullish that this trend will continue for many years to come. And before we turn to the outlook, CBORD did very well in the quarter on increases in their recurring subscription revenues. Of importance, we announced a partnership with Apple whereby the students’ and the faculty’s security and payments credentials can be on-boarded into the Apple Wallet. Six universities Clemson, University of San Francisco, University of Tennessee Knoxville, University of Vermont, MIT, and University in Kentucky have or are adopting this technology for this full year. For CBORD, this opens up a new recurring revenue stream as each credential is activated. Though very early, this could prove to be a nice long-term growth driver for CBORD. And finally, and we have to highlight the tremendous, just excellent cash performance in the quarter from CBORD. Great job and congrats to Jim, Rob and the entire team there. As we turn to the outlook, we want to highlight that Deltek and Aderant were benefited by the acceleration of a few high margin perpetual transactions. These transactions were in the sales funnel at the end of last quarter but the timing of which is always difficult to pinpoint. So we assumed they were closed in Q4. But they were executed in Q3. Notwithstanding, we continue to expect mid-single-digit organic increases for this segment in Q4. Next slide, please. Turning to our Network segment, revenue in our Network Software & Systems segment for the quarter were $394 million, an increase of 4% on an organic basis. EBITDA was $176 million increasing 15% versus the prior year, and EBITDA margins were 44.7%. During the quarter, we acquired iPipeline for $1.625 billion. iPipeline, we’ll report it in this segment, and we'll discuss iPipeline in detail on the following slide. The quarter was highlighted by continued growth in our DAT or North American freight match business. In particular, we saw strength in demand for a rate data offering which helped drive increased ARPU in the quarter. Foundry also started strong with double-digit revenue growth in their first full quarter as part of Roper. In particular, there was nice growth across both their media and entertainment core vertical, and their emerging digital design business. Also in the quarter, Jody and the team delivered major releases to both their Nuke and Katana product offering. iTrade grew double-digits in the quarter based on strong renewal activity and new customer adds. MHA’s performance in the quarter was highlighted by several strong trends. To remind everyone, MHA is the largest group purchasing network for the non-hospital market with leadership positions and long-term care pharmacies, long-term care facilities and home infusion marketplaces. The team continues to win the market share gain relative to on-boarding new and startup pharmacies. Importantly, in the quarter, MHA continued to see the benefits of increased customer purchasing volumes due to several new pharmaceutical products being on contract. Also, it's worth reminding everyone about the favorable end market conditions, essentially the aging of America and the increasing demands this aging demographic puts on the healthcare system. This trend benefits MHA. Finally, the President of MHA, Mike Sicilian announced his intention to retire from the business. Mike has been the MHA President since our acquisition in 2013 and has done a terrific job growing MHA and providing leadership to both SoftWriters and SHP. Congrats to Mike for a wonderful career with MHA and Roper. And Mike, thank you. His successor Diane Koontz has been MHA's COO for the GPO business for several years. As a result, MHA's leadership succession plan has been seamless, which is a testament to Mike and Diane working together in pursuit of this transition for several quarters. Turning to RF IDeas, we continue to see strength in this business. In fact, another record quarter for RF IDeas. The strength was based on continued adoption of RF Ideas’ core reader technology in secure print and secure sign on applications. This is another very good example of a leadership niche business and in this case Roper style products business. Great job by the team. And finally, in the quarter TransCore was down low single-digits based on project timing. Importantly TransCore was recently awarded with the design, implementation and maintenance contract for New York City’s Central Business District Tolling Program. The total contract value was approximately $507 million and we expect to recognize approximately $200 million of revenue associated with this contract next year. The recurring revenue operations and maintenance portion of the contract will commence in early 2021 and run for a minimum of six years. Thank you to the MTA for trusting TransCore to deliver on this very important and highly visible contract. And also congratulations to Tracy and the entire TransCore team for building the products and technologies needed to implement this project as well as the many years of experience integrating similar solutions. As we return to the outlook, we continue to expect mid single-digit organic growth for this segment in the final quarter of the year. Next slide please. iPipeline is a wonderful addition to our growing stable of software businesses. iPipeline is a leader in cloud-based software solutions for the life insurance industry. Specifically, iPipeline provides the necessary workflow automation solutions needed to quote, apply, underwrite and manage life insurance products. The software solutions enable very broad network of carriers, distributors and agents in the sales and delivery of life insurance products. The purchase price was $1.625 billion and is immediately cash accretive. We expect the business to grow in the high single-digit range and this is based on the company's long history of revenue, EBITDA and cash flow growth. For 2020, we expect iPipeline to deliver approximately $200 million in revenue at roughly 40% EBITDA margins and generate approximately $70 million of after-tax unlevered free cash flow. Importantly, iPipeline is a Roper style software business. They have very strong cash flow characteristics and is very asset light, in fact negative net working capital. The management teams led by Larry Berran exemplify what we look for in our leaders. Long-term commitment to solving customer problems with solutions that have recurring revenue streams, teams that love to build great businesses. They are the clear leader in this niche vertical and as a result have very deep domain knowledge. And given this, they have very high levels of recurring revenue and their customer intimacy provides clear opportunities to continually enhance the products and solutions to continue to grow over the long-term. We've been tracking this business for several years and are excited to welcome the team to Roper. Next slide please. Revenue in the quarter in our Measurement & Analytic Solutions segment were $389 million, a decrease of 2% on an organic basis. EBITDA was $137 million, a decrease of 6% versus the prior year and EBITDA margins were 34.4%. Verathon had a strong quarter whose growth was led by increases in their GlideScope consumables recurring revenue. In addition, the Verathon team has done a nice job launching their new single use bronchoscope product line, well on path to becoming a meaningful product for Verathon within the first year of launch. NDI had another great quarter. This quarter’s strength was rooted in NDI’s electromagnetic and optical measurement systems used by several OEMs in surgical applications. Great job again by the NDI team. Our CIVCO MMI business in Iowa City had a very nice quarter that was highlighted by strong execution in their ultrasound guidance market. Neptune did well in the quarter especially coming off a strong double-digit comp from a year ago, but the quarter's growth was hampered by supply chain constraints specific to their newer ultrasonic residential meter offering. Of note, over the past couple of years Neptune has invested to develop a static meter based on ultrasound technology for both the residential and larger commercial and industrial meter markets. In the quarter Neptune saw bookings for ultrasonic meters outstripped their current production capacity, which we view as generally a good thing as this newer product appears to be striking a positive chord with several new customers. The Neptune operating and supply chain teams are working aggressively to boost production, which we expect to see the benefit of as we head into 2020. All-in-all, a good quarter for Neptune. As we expected our short cycle industrial businesses declined high single-digits. This performance was consistent with the last part of last quarter and consistent with our expectations heading into Q3. The business has started taking cost actions in Q3 and will continue into Q4 to best position these businesses for 2020. Importantly, this group did a tremendous job managing margins in the quarter. As we have discussed, we reached an agreement to sell Gatan to AMETEK for $925 million. We expect the sale to close at the end of this month. Given the backdrop of a two-year sales process and a very intensive divestiture workload over the last three to four months, the Gatan business had a challenging third quarter down high single-digits as volume shifted out of Q3 and into Q4. We expect most of these delayed shipments to occur after the closing of the divestiture. As we turn to our guidance, we see organic revenues flat for the fourth quarter. We see our medical product business is growing mid single-digit plus for the final quarter of the year. We expect Neptune to grow low single-digits as they are working to expand their static meter supply chain capacity and we expect our short cycle industrial businesses to be down high single-digits. Finally, as we mentioned before, we expect the divestiture of Gatan to close later in this month. Of note, Gatan's annual EBITDA has historically been extremely back-end weighted through the last two months of the year, a period we do not expect to own in 2019. Next slide please. And finally revenue for our Process Technologies segment for the quarter were $160 million, a decrease of 5% on an organic basis. EBITDA was $58 million, a decrease of 3% versus prior year and EBITDA margins were 36.6%, an increase of 100 basis points. We saw very strong actually outstanding margin performance for this group of businesses in the quarter. This was driven by our business unit leadership teams executing to remove cost from the businesses on a rapid basis. To this end and it's always worth reminding everyone the vast majority of our businesses’ cost structure are variable. For this reason when times are good we tend to only have modest incrementally positive leverage, but this meaningfully benefits us when times get more challenging. We are able to quickly take cost out of the system and position the businesses in the most optimal manner. The teams did a great job of this in the quarter. Relative to CCC we continue to see strength in their LNG project pipeline and we are the contracted vendor in essentially all new projects coming online over the next several years. Finally and prior to turning to our guidance, we are excited to announce new presidents at both our PAC and CCC businesses. Both businesses have and continue to perform well, but the addition of Ed and Pete to our team should greatly enhance these two businesses’ ability to develop and deploy strategy, drive targeted operational improvements, and simplify the operational complexity of each of these businesses. Welcome to both Ed and Pete to the Roper family. Turning to our outlook, we do see and expect a weakened outlook for upstream oil and gas businesses as we head into Q4. Given this we are guiding to mid single-digit organic revenue declines in this segment for Q4. Next slide please. Core guidance, we are tightening our DEPS guidance to a range of $12.98 to $13.02 compared to our prior guidance of $12.94 to $13.06. Also for establishing Q4 adjusted DEPS guidance to be in the range of $3.32 to $3.36. Please note that Q4 and the full year guidance includes an $0.08 headwind based on the net impact of our Q3 acquisitions and the Q4 divestiture of Gatan. Finally we expect our tax rate to be approximately 22% in the quarter. Next slide please. As we turn to our final slide before Q&A. We continue to see strength in our niche market strategy and governance model that promotes nimble local execution. This led to strong performance in the quarter across the enterprise. EBITDA margins were up 90 basis points to 36.7%. DEPS grew 6% to $3.29 and TTM free cash flow increased by 12%. Also and importantly, we successfully deployed $1.8 billion for two terrific Roper like software businesses in the quarter, ComputerEase and iPipeline. Finally in the quarter we were able to reach an agreement with AMETEK to divest Gatan for $925 million and complete a $1.2 billion bond offering is a very attractive long-term rate. Great execution across the entire enterprise in the quarter. As we look towards 2020, we see several encouraging trends. First, our enterprise continues to be less and less exposed to macro cyclical impacts as our expanding software portfolio increases our recurring revenue mix. This is a longer-term trend that we feel great about. Next, our balance sheet remains very strong and will only be strengthened by the Gatan divestiture proceeds. Further, our acquisition pipeline remains very strong with several high quality opportunities across various stages of deal maturity. We continue to see a very large number of very high quality assets. And finally, TransCore's New York City congestion pricing infrastructure project will drive meaningful revenue, approximately $200 million for the enterprise, beginning in 2020. Now as we turn to questions we want to remind everyone that what we do is very simple. We compound cash flow by running a portfolio of operating businesses that have market-leading positions and niche industry. We provide the business leaders with Socratic coaching about what great looks like relative strategy, operations, innovation and talent development. We incent our management teams based on growth. We have a culture of mutual trust and transparency. And finally, we take our excess free cash flow and deploy it to buy businesses that have better cash returns than our existing company. These simple ideas deliver powerful results. Now, let's turn the call over to your questions.